Breast Cancer

Amy Comander, MD, shares her thoughts on key developments in breast cancer care that took place in 2021, and reflects on what the future might hold for this patient population

Remedying gaps in knowledge and implementing strategies for financial toxicity mitigation are important for optimizing breast cancer treatment.

Patient Case 2 is presented, and Dr Gadi and Dr Mahtani detail how they would proceed with treating this patient.

Patient Case 1 is presented to the panel, and Vijayakrishna Gadi, MD, PhD, shares his thoughts on how to approach treatment of this patient.

Patients with HER2-mutant breast cancer given neratinib combinations saw improved efficacy.

Paolo Tarantino, MD, hosted a Twitter Takeover during the San Antonio Breast Cancer Symposium where he discussed abstract presentations and key takeaways in a #CNRealTimeReport.

CancerNetwork® looks back on some of the promising, ongoing pieces of clinical research within the breast cancer space from 2021.

Reshma Mahtani, DO, discusses considerations for use of trastuzumab duocarmazine in HER2+ breast cancer.

Our panel of experts review the latest data on the antibody drug conjugate, trastuzumab duocarmazine.

Reshma Mahtani, DO, and Neil Iyengar, MD, discuss the data presented at ESMO 2021 in the TUXEDO-1 and HER2CLIMB-04 trials.

The panel analyzes the data from DESTINY-Breast03 and DESTINY-Breast01 and how these data will further impact practice.

Research from the 2021 San Antonio Breast Cancer Symposium suggests pathologic complete response and event-free survival were not significantly impacted by race for women with high-risk breast cancer who underwent targeted neoadjuvant chemotherapy.

Patients with gremlin BRCA1/2 mutations and high-risk HER2-negative early breast cancer can have amenable adverse effects after being treated with chemotherapy before utilize olaparib.

Investigators were able to identify breast cancer immunohistochemistry markers including Ki-67, estrogen receptor, and progesterone receptor status utilizing deep learning–based artificial intelligence algorithms

Patients with hormone receptor-positive breast cancer who were treated with samuraciclib plus fulvestrant saw tumor activity.

Findings from the SqeDCIS trial indicated that DCISionRT was predictive of radiotherapy benefit in patients with ductal carcinoma in situ of the breast.

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer saw a survival benefit when treated with adjuvant chemotherapy.

Utilizing aromatase inhibitors compared with tamoxifen reduce recurrence in estrogen receptor-positive breast cancer in patients who were menopausal and received ovarian suppression.

Black patients may have poorer outcomes during breast cancer treatment than White patients.

Research presented at the 2021 San Antonio Breast Cancer Symposium highlighted survival improvements for postmenopausal women with hormone receptor–positive HER2-negative advanced breast cancer when treated with ribociclib plus letrozole over placebo.

Those with higher Oncotype DX scores may be more likely to complete the recommended 5 years of endocrine therapy for breast cancer.

Pooled efficacy and safety data confirm that patients who self-identify as Black or Hispanic can be safely treated with palbociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer.

Experts close out their discussion on the management of HER2+ metastatic breast cancer by highlighting their hopes for future treatment strategies.

Centering their conversation on a patient case, experts discuss the sequencing and monitoring of therapy in patients with HER2+ metastatic breast cancer.

Panelists field questions from a live audience regarding the optimal selection of therapy for patients with metastatic breast cancer.